Mortality rate related to peripheral arterial disease: A retrospective analysis of epidemiological data (years 2008-2019).

BACKGROUND AND AIMS Peripheral arterial disease (PAD) is one of the most prevalent cardiovascular diseases with more than 230 million people being affected worldwide. As highlighted by the recent European Society of Cardiology guidelines, data on the epidemiology of PAD is urgently needed. METHODS AND RESULTS We accessed the vital registration data of the Veneto region (Northern Italy, approximately five millions inhabitants) covering the period 2008-2019. We computed annual age-standardized rates for PAD reported as the underlying cause of death (UCOD) or as one of multiple causes of death (MCOD). Age-adjusted odds ratios (OR) served to study the association between PAD and cardiovascular comorbidities. The age-standardized mortality rate for PAD as MCOD slightly declined from 19.6 to 17.8 in men and from 10.8 to 9.1 deaths per 100,000 population-years in women. The age-standardized PAD-specific mortality rate (UCOD) remained stable: 3.1 to 3.7 per 100,000 person-years in women (Average Annual Percent Change 1.3, 95% CI -0.8; 3.4%) and 4.4 to 4.3 per 100,000 person-years (Average Annual Percent Change -0.2, 95% CI -3.6; 3.4%) in men. PAD contributed to 1.6% of all deaths recorded in the region. Ischemic heart disease, diabetes mellitus and neoplasms were the most prevalent UCOD among PAD patients. PAD was associated with diabetes mellitus (OR 3.79, 95%CI 3.55-4.06) and chronic kidney diseases (OR 2.73, 95%CI 2.51-2.97) in men, and with atrial fibrillation (OR 2.26, 95%CI 2.10-2.44) in women. CONCLUSION PAD remains a substantial cause of death in the general population of this high-income region of Western Europe with marked sex-specific differences

EU project "Cheap-GSHPs": the geoexchange field laboratory

Abstract The Molinella test site is the open-air laboratory of the EU project entitled "Cheap-GSHPs: Cheap and Efficient Application of Reliable Ground Source Heat Exchangers and Pumps". Here, innovative helical heat baskets and steel coaxial probes are installed next to the traditional double-U. The tests involve the probes design as well as materials and drilling techniques and machines, therefore the newly developed GSHEs can be directly compared with the traditional ones with respect to technical issues and energetic performances. The Molinella test site therefore represents a very extraordinary possibility to improve the knowledge of heat transfer processes in shallow geo-exchange systems

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

INTRODUCTION The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients remain unclear. We present the 90-day results from the randomised, open-label, parallel-group, investigator-initiated, multinational OVID phase III trial. METHODS Outpatients aged 50 years or older with acute symptomatic COVID-19 were randomised to receive enoxaparin 40 mg for 14 days once daily vs. standard of care (no thromboprophylaxis). The primary outcome was the composite of untoward hospitalisation and all-cause death within 30 days from randomisation. Secondary outcomes included arterial and venous major cardiovascular events, as well as the primary outcome within 90 days from randomisation. The study was prematurely terminated based on statistical criteria after the predefined interim analysis of 30-day data, which has been previously published. In the present analysis, we present the final, 90-day data from OVID and we additionally investigate the impact of thromboprophylaxis on the resolution of symptoms. RESULTS Of the 472 patients included in the intention-to-treat population, 234 were randomised to receive enoxaparin and 238 no thromboprophylaxis. The median age was 57 (Q1-Q3: 53-62) years and 217 (46 %) were women. The 90-day primary outcome occurred in 11 (4.7 %) patients of the enoxaparin arm and in 11 (4.6 %) controls (adjusted relative risk 1.00; 95 % CI: 0.44-2.25): 3 events per group occurred after day 30. The 90-day incidence of cardiovascular events was 0.9 % in the enoxaparin arm vs. 1.7 % in controls (relative risk 0.51; 95 % CI: 0.09-2.75). Individual symptoms improved progressively within 90 days with no difference between groups. At 90 days, 42 (17.9 %) patients in the enoxaparin arm and 40 (16.8 %) controls had persistent respiratory symptoms. CONCLUSIONS In adult community patients with COVID-19, early thromboprophylaxis with enoxaparin did not improve the course of COVID-19 neither in terms of hospitalisation and death nor considering COVID-19-related symptoms

Thermal Response Testing Results of Different Types of Borehole Heat Exchangers: An Analysis and Comparison of Interpretation Methods

The design phase of ground source heat pump systems is an extremely important one as many of the decisions made at that time can affect the system’s energy performance as well as installation and operating costs. The current study examined the interpretation of thermal response testing measurements used to evaluate the equivalent ground thermal conductivity and thus to design the system. All the measurements were taken at the same geological site located in Molinella, Bologna (Italy) where a variety of borehole heat exchangers (BHEs) had been installed and investigated within the project Cheap-GSHPs (Cheap and efficient application of reliable Ground Source Heat exchangers and Pumps) of the European Union’s Horizon 2020 research and innovation program. The measurements were initially analyzed in accordance with the common interpretation based on the first-order approximation of the solution for the infinite line source model and then by utilizing the complete solutions of both the infinite line and cylinder source models. An inverse numerical approach based on a detailed model that considers the current geometry of the BHE and the axial heat transfer as well as the effect of weather on the ground surface was also used. Study findings revealed that the best result was generally obtained using the inverse numerical interpretation

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.

INTRODUCTION The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients remain unclear. We present the 90-day results from the randomised, open-label, parallel-group, investigator-initiated, multinational OVID phase III trial. METHODS Outpatients aged 50 years or older with acute symptomatic COVID-19 were randomised to receive enoxaparin 40 mg for 14 days once daily vs. standard of care (no thromboprophylaxis). The primary outcome was the composite of untoward hospitalisation and all-cause death within 30 days from randomisation. Secondary outcomes included arterial and venous major cardiovascular events, as well as the primary outcome within 90 days from randomisation. The study was prematurely terminated based on statistical criteria after the predefined interim analysis of 30-day data, which has been previously published. In the present analysis, we present the final, 90-day data from OVID and we additionally investigate the impact of thromboprophylaxis on the resolution of symptoms. RESULTS Of the 472 patients included in the intention-to-treat population, 234 were randomised to receive enoxaparin and 238 no thromboprophylaxis. The median age was 57 (Q1-Q3: 53-62) years and 217 (46 %) were women. The 90-day primary outcome occurred in 11 (4.7 %) patients of the enoxaparin arm and in 11 (4.6 %) controls (adjusted relative risk 1.00; 95 % CI: 0.44-2.25): 3 events per group occurred after day 30. The 90-day incidence of cardiovascular events was 0.9 % in the enoxaparin arm vs. 1.7 % in controls (relative risk 0.51; 95 % CI: 0.09-2.75). Individual symptoms improved progressively within 90 days with no difference between groups. At 90 days, 42 (17.9 %) patients in the enoxaparin arm and 40 (16.8 %) controls had persistent respiratory symptoms. CONCLUSIONS In adult community patients with COVID-19, early thromboprophylaxis with enoxaparin did not improve the course of COVID-19 neither in terms of hospitalisation and death nor considering COVID-19-related symptoms

Modelling high-resolution spatially-resolved Supernova Remnant spectra with the Sardinia Radio Telescope

Supernova Remnants (SNRs) exhibit spectra featured by synchrotron radio emission arising from the relativistic electrons, and high-energy emission from both leptonic (Bremsstrahlung and Inverse Compton) and hadronic processes (π0 mesons decay) which are a direct signature of cosmic rays acceleration. Thanks to radio single-dish imaging observations obtained in three frequency bands (1.6, 7, 22 GHz) with the Sardinia Radio Telescope (www.srt.inaf.it), we can model different SNR regions separately. Indeed, in order to disentangle interesting and peculiar hadron contributions in the high-energy spectra (gamma-ray band) and better constrain SNRs as cosmic rays emitters, it is crucial to fully constrain lepton contributions first through radio-observed parameters. In particular, the Bremsstrahlung and Inverse Compton bumps observed in gamma-rays are bounded to synchrotron spectral slope and cut-off in the radio domain. Since these parameters vary for different SNR regions and electron populations, spatially-resolved radio spectra are then required for accurate multi-wavelength modelling

The high-frequency upgrade of the Sardinia Radio Telescope

We present the status of the Sardinia Radio Telescope (SRT) and its forthcoming update planned in the next few years. The post-process scenario of the upgraded infrastructure will allow the national and international scientific community to use the SRT for the study of the Universe at high radio frequencies (up to 116 GHz), both in single dish and in interferometric mode. A telescope like SRT, operating at high frequencies, represents a unique resource for the scientific community. The telescope will be ideal for mapping quickly and with relatively high angular resolution extended radio emissions characterized by low surface brightness. It will also be essential for spectroscopic and polarimetric studies of both Galactic and extragalactic radio sources. With the use of the interferometric technique, SRT and the other Italian antennas (Medicina and Noto) will operate within the national and international radiotelescope network, allowing astronomers to obtain images of radio sources at very high angular resolution